Bora Pharmaceuticals (TPE:6472) denied a media report valuing its strategic alliance with AI drug discovery firm Insilico Medicine at more than $2.5 billion, according to a Wednesday Taiwan Exchange filing.
The pharmaceutical company said the Commercial Times report does not represent company-issued financial projections.
Bora said it does not release financial forecasts or business projections and advised investors to refer to its filings on Taiwan's Market Observation Post System for official financial and business information.